iLite® ADCC Bioassays Greater than the sum of its parts 

iLite® ADCC Portfolio

In antibody-dependent cell-mediated cytotoxicity (ADCC), Fc receptor-bearing effector cells recognize and kill antibody-coated target cells that express tumor or pathogen-specific antigens on their surface. The iLite ADCC product portfolio is based on a reporter gene system and offers a convenient and powerful way of measuring the efficacy of antibodies to elicit ADCC in vitro.

This is achieved by combining a cleverly engineered effector cell that closely resembles the natural FcγRIIIA signal transduction pathway, with homologous target cells and controlled antigen expression (+) or depletion (-). Taken together, our unique iLite ADCC portfolio offers unparalleled sensitivity for each target and system that is truly greater than the sum of its parts.


Each cell line in the iLite ADCC product portfolio, is provided in “assay-ready” format for a rapid and convenient workflow and further reduction in assay variability, enabling their use in antibody screening, characterization, stability and potency studies.

We are continuously expanding the iLite® ADCC portfolio with novel and highly specific target cells and can also accommodate most customers request for using in-house/pre-qualified target cells and support that in a cryopreserved assay ready format.


(CD16a, V158 variant)

An engineered Effector Cell, more closely reflects the FcγRIIIA, the main receptor involved in ADCC, signal transduction pathway. This receptor is expressed predominantly by NK cells.



CD20 is a surface antigen primarily found on B-cells. Anti-CD20 monoclonal antibodies have been developed such as Rituximab -  which is a therapy for cancer, targeting CD20 expressed on B-cell non-Hodgkin lymphoma (NHL).



EGFR is a well-established target for monoclonal antibodies, such as Cetuximab and specific tyrosine kinase (a type of enzymes important in the cell signaling cascade) inhibitors.




HER2 plays a critical role in cellular growth and is frequently up regulated in numerous cancers, ex breast cancers. The monoclonal antibody, Trastuzumab, is the most well-known drug for targeting HER2/ErbB2-positive breast cancer.



Anti-TNF-α antibodies, such as adalimumab, infliximab etc.  may bind to membrane bound TNF-α in addition to binding the soluble TNF-α. It is important to determine the effects of such binding, and if activation of antibody-dependent cellular cytotoxicity (ADCC) may arise. 



 mVEGF  Vascular endothelial growth factor A (VEGF-A)is signal protein that stimulates the formation of blood vessels. The anti-VEGF antibody, Bevacizumab, is a therapeutic antibody that works by slowing the growth of new blood vessels by inhibiting VEGF-A


Why the need for an ADCC assay?

The activity of many antibody-based therapeutics is mediated in part by their ability to induce ADCC and thereby enhancing the body’s own immune response towards dysfunctional cells.

By analyzing the ADCC activity induced by different drugs or drug candidates, a measure of both drug potency and unwanted side effects can be provided and the suggested ADCC mechanism of the drug candidate can be established.

Another area where ADCC assays are important is in the development of biosimilars. There are extensive regulatory requirements in place for analytical characterization of the innovator drug and its biosimilar.

The iLite ADCC product line is a valuable tool for the whole drug development process. It can be used to measure the ability of a drug to induce ADCC activity in a straightforward, sensitive and reproducible manner.

Traditional methods vs iLite Technology

Traditional methods used to measure ADCC use primary donor peripheral blood mononuclear cells (PBMCs) or purified natural killer (NK) cells that express Fc receptors on their cell surface. The killing of target cells is an endpoint of this pathway activation and these primary cell-based assays are highly variable in response, tedious to prepare and can result in high background readings.

The desire for targeted therapy in, for example, cancer has spurred the development of monoclonal antibodies and many have targeted cell surface-expressed antigens found on tumor cells, due to their relative accessibility and specificity.

To overcome many of the limitations of these traditional methods and meet the need of a more robust and reliable assay, Svar Life Science have developed engineer Effector Cells expressing the FC receptor and a suite of specific positive Target Cell as well as a negative control cell line for a number of targets. These targets cells allow screening for specific as wells as unspecific activation of ADCC, giving added value to each experiment.

iLite Technology, delivering optimal ADCC bioassays!

The iLite ADCC bioassay portfolio possesses all the hallmarks of optimal bioassays - excellent linearity, large dynamic window, specificity, repeatability, precision and accuracy - and introduces unique engineered homologues Target (+) and (-) Cells for a more complete picture of the intracellular events.
It is an ideal assay for applications such as potency lot release and antibody screening, as well as for assessing comparability between innovator and biosimilars. Furthermore, the bioassay can be used to assess the impact of post-translational modifications, such as glycosylation and fucosylation, on the potency of monoclonal antibodies (mAbs).


cellular cytotoxicity


The technology behind


Application areas

Can´t find a perfect match? Let us develop it for you!

In case you haven't got an ideal target cell line and can't find what you’re looking for in our off the shelf solution, you can rely on our extensive expertise to develop the most appropriate one and we have vast experience in designing cell lines ideally fit for purpose!

Contact us